Reiferon Retard® is indicated for the treatment of chronic hepatitis C in adult patients who are positive for serum HCV‐RNA, including patients with compensated cirrhosis. The optimal way to use Reiferon Retard® in patients with chronic hepatitis C is in combination with Ribavirin. The combination of Reiferon Retard® and Ribavirin is indicated in naive patients and patients who have failed previous treatment with interferon alpha (pegylated or non‐pegylated) alone or in combination with Ribavirin.

COMPOSITION:

Pegylated Hansenula‐derived recombinant interferon alfa‐2a 160 μg

Excipients: /ml

• Sodium chloride 8.00 mg
• Polysorbate 80 0.05 mg
• Benzyl alcohol 10.00 mg
• Sodium acetate trihydrate 2.62 mg
• Acetic acid 0.05 mg

INDICATIONS:

Chronic hepatitis C:

Reiferon Retard® is indicated for the treatment of chronic hepatitis C in adult patients who are positive for serum HCV‐RNA, including patients with compensated cirrhosis. The optimal way to use Reiferon Retard® in patients with chronic hepatitis C is in combination with ribavirin. The combination of Reiferon Retard® and ribavirin is indicated in naive patients and patients who have failed previous treatment with interferon alpha (pegylated or non‐pegylated) alone or in combination with Ribavirin.

Monotherapy is indicated mainly in case of intolerance or contraindication to ribavirin.

DOSAGE AND ADMINISTRATION:

Chronic hepatitis C:

The recommended dose of Reiferon Retard® when used in combination with ribavirin is one vial (160 μg) once weekly or as indicated by the prescribing physician.

The daily dose of ribavirin is 800 mg to 1200 mg administered orally in two divided doses. The dose should be individualized to the patient depending on baseline disease characteristics (e.g. genotype), response to therapy and tolerability of the regimen. Since absorption of ribavirin increases when administered with a meal, patients are advised to take ribavirin with food.